Search results
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials...
Morningstar· 1 day agoFN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at ...
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
Zacks via Yahoo Finance· 4 days agoShattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute ...
Treatment of Blood Cancers
Digital Journal· 6 hours agoVancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases the ...
Blincyto Picks Up New BCP-ALL Indication
Medscape· 14 hours agoThe agent is the first BiTE approved for consolidation regardless of MRD status.
Hemogenyx Pharmaceuticals PLC Announces Operations Update
Digital Journal· 2 days agoOperations Update LONDON, UNITED KINGDOM / ACCESSWIRE / June 17, 2024 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to provide an update on its
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology...
Digital Journal· 4 days agoTUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's...
Benzinga· 1 day agoShares of Ovid Therapeutics Inc OVID dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint. Takeda Pharmaceutical Co Ltd TAK announced topline data ...
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
WKRN Nashville· 4 days agoThe oral presentation includes five-year results from the pivotal cohort of the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) for the treatment of relapsed or refractory (R/R) mutated ...
Why Is Bio-Path (BPTH) Stock Up 20% Today?
InvestorPlace· 4 days agoBio-Path (NASDAQ:BPTH) stock is rising higher on Friday alongside data from the oncology-focused company’s Phase 2 clinical trial of prexigebersen....
Syndax reports encouraging results from AML treatment trials By Investing.com
Investing.com· 4 days agoSyndax Pharmaceuticals (NASDAQ: NASDAQ:SNDX), a clinical stage biopharmaceutical company, has...
